Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

February 28, 2023

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 73 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and thanks for joining us today. Welcome to Bayer's investor and analyst call covering the full year and Q4 2022 results. Right now, everyone is in listen-only mode. Once the speaker finishes presenting, we'll open it up for questions and answers. If you'd like to ask something during that part, just press star one and one on your phone. An automated message will then confirm that your hand is raised. Should you want to take your question back, press star one and one once more. Please note that this conference is being recorded today. I'll now turn things over to Oliver Maier, who leads Investor Relations at Bayer AG. Over to you.

Oliver Maier

executive
#2

Okay, thanks a lot, Heidi. Good afternoon, everyone, and thank you for being with us today. I want to extend a welcome to each of you for our conference call covering the fourth quarter and the full year 2022. Joining me on today's call are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO, as well as our division heads. Werner will start things off with the key achievements of 2022. As we introduced last year, Rodrigo, Stefan, and Heiko will then each comment on how their respective divisions performed and on the outlook for 2023. Wolfgang will wrap up with an overview of group performance and the outlook before we open things up for the Q&A session. As usual, I'd like to point you to the cautionary language contained in our safe harbor statement, as well as in all the materials we've distributed today. With that, Werner, over to you.

Werner Baumann

executive
#3

Okay. Thanks, Oliver, and good afternoon, everyone. I'm glad to have you join today's conference call. The year 2022 brought unmatched volatility at the macro level along with geopolitical difficulties. The war Russia launched in Ukraine — a country that ranks among the leading exporters of essential crops — dealt a serious blow to food security around the world. Sanctions imposed on Russia created risks for energy supplies, particularly at our European-based operations. Meanwhile, the COVID-19 pandemic carried on, and large-scale lockdowns, for instance in China, put even more strain on global supply chains. Those macro developments drove faster inflation across the globe, which pushed central banks in major economies to raise their target interest rates. Against that background, our business model held up very strongly, with solutions that tackle the most urgent challenges worldwide in nutrition and healthcare. Our vision, Health for All — Hunger for None, has rarely been as pertinent as it is in times such as these. For Bayer, 2022 turned out to be an outstanding year in fact, operationally as well as strategically. We met our ambitious financial targets, which we had raised in August. Sales came to EUR 51 billion, an increase of 9% on a currency and portfolio adjusted basis, set against an already strong prior year. Crop Science drove that growth, with a solid contribution also from Consumer Health, while the Pharmaceuticals top line landed slightly above the previous year.

Werner Baumann

executive
#4

Within Crop Science, the expansion mostly came from pricing—both for glyphosate relative to herbicides and across the rest of the portfolio. Consumer Health gained from robust demand for allergy and cold products along with growth in our launch brands. In Pharmaceuticals, Eylea kept surpassing what we had expected and posted growth in every region. Our newer pharma products built additional encouraging momentum, with combined Nubeqa and Kerendia sales passing the half billion EUR mark in 2022. That in fact helped counter near-term headwinds—volume-based procurement effects in China and the loss of exclusivity for Xarelto in Brazil—which proved larger than we had foreseen at the start of 2022. EBITDA before special items rose 21% year-on-year, reaching EUR 13.5 billion. Thanks to strong pricing leverage and savings from our efficiency programs, we offset roughly EUR 2 billion of cost inflation while still delivering significant earnings growth. As a result, core earnings per share reached EUR 7.94, comfortably ahead of our full-year expectations. Given this strong operational performance, we are proposing to shareholders a 20% dividend increase, to EUR 2.40 per share. We also achieved further meaningful progress on sustainability. We remain well on track to meet our 2030 non-financial targets.

Werner Baumann

executive
#5

I'd like to direct your attention to the new sustainability report we released today. Turning to innovation, I'll highlight a few key points and give some additional perspective. Encouraged by positive study data from 2022, we have lately increased the peak sales estimate for our main short- and midterm growth drivers in Pharmaceuticals to more than EUR 12 billion. We anticipate that half of that growth potential will be generated by Nubeqa and Kerendia, our recently introduced products. The remaining half should arise from our phase III assets, Asundexian and elinzanetant. During 2023 — as we just saw yesterday in Japan — we anticipate additional approvals for Nubeqa in metastatic hormone-sensitive prostate cancer across multiple geographies. We recently shared new data that confirm survival benefits along with the favorable safety profile of Nubeqa among different patient subgroups in this indication. We have also filed the Eylea 8 mg formulation for regulatory approval in two major retinal eye diseases in the EU, with possible first launches during 2023. Finally, we expect readouts in 2023 from our Parkinson's phase I studies and from the elinzanetant phase III studies for menopause management. In Crop Science, we will begin on-farm trials in the U.S. this year for our short stature corn.

Werner Baumann

executive
#6

We also anticipate the complete commercial rollout of our inaugural biotech trait targeting piercing sucking insects. Our first digital B2B solutions will be introduced as part of the Microsoft collaboration. In Consumer Health, we'll keep advancing the Astepro launch during the coming U.S. allergy season. Later this year, we also intend to introduce an innovative personalized health offering. Consistent with our strategic agenda, innovation doesn't come solely from inside the company, since we keep investing externally to strengthen our research collaborations. Our lease portfolio grew once more, with seven companies added during 2022. We formed a multi-year strategic partnership with Ginkgo Bioworks, a Boston-based biotech company, and acquired a majority stake in CoverCress, which produces a sustainable oilseed cover crop. Meanwhile, we continued optimizing our portfolio by selling the Environmental Science Professional business along with some non-core pharma assets. Turning to 2023: following two years of recovery and dynamic top-line development, we anticipate additional growth in the current year, though at normalized rates. The environment looks more challenging, with glyphosate prices softening. We anticipate additional price reductions across our mature pharma portfolio, partly offset by new product growth plus pricing and volume contributions elsewhere.

Werner Baumann

executive
#7

With that in mind, we don’t anticipate EBITDA before special items or Core EPS hitting the record levels seen in 2022, though they should still stay above our midterm planning. My colleagues will now discuss how each business performed and what the outlook looks like. Rodrigo, over to you to begin with Crop Science.

Rodrigo Santos

executive
#8

Thank you, Werner, and I appreciate all of you being with us today. For us, 2022 proved to be an outstanding year. It's my pleasure to report that we fulfilled our twin pledges — to perform and to transform — within agriculture. On the performance side, Crop Science posted yet another record year, exceeding EUR 25 billion in sales, with CPA sales growth of 15.6%, which came in ahead of our latest guidance of 13%. That sales increase was powered by pricing, as we carried out our innovation-driven, value-based pricing strategy and successfully navigated the market dynamics surrounding our glyphosate-based herbicides. Close to 2/3 of the growth in sales — or roughly EUR 2 billion — was generated by higher glyphosate pricing stemming from tight global supply. At the same time, fungicides and insecticides each posted 5% sales growth. The remainder of our herbicide portfolio rose by 11%. Had supply been better, we could easily have recorded high single-digit growth in insecticides and fungicides, given how strong demand was. Turning to seed and traits, our global corn business expanded its number one share position in the market, delivering CPA sales growth of nearly 9%. Within the U.S., stronger pricing more than offset lower planted corn acres as well as a decline in royalties from certain older licensees. Across all other regions, we achieved corn growth rates of 20% or more, reflecting our strong mix of volume gains and price increases.

Rodrigo Santos

executive
#9

When it comes to soybean, we kept our number one spot even though global sales were flat, hitting over 80% of Brazil's acres and nearly 50% of U.S. acres with our trait technologies. Then there's cotton — that business posted growth of almost EUR 100 million, which is above 15%. That came in 2022 from pricing and also from bigger volumes driven by more planted acres in the U.S. and Australia. This robust pipeline growth, together with roughly EUR 200 million in cost savings from the transformation programs we have underway, gave us an industry-leading 27% EBITDA margin before special items, right in line with our guidance, and more than offsetting about EUR 1 billion in added cost inflation plus 110 basis points of margin pressure from FX. On top of that, through careful management — especially of receivables — our twelve-month average working capital to sales ratio fell from about 49% down to 42% by the close of 2022, a gain of 640 basis points. Our ongoing push to reshape the industry has been just as remarkable. Every single year, our R&D team brings customers more innovation than anyone else in this space. The EUR 2.6 billion we invested in R&D during 2022 keeps moving forward a pipeline whose long-term peak sales potential exceeds EUR 30 billion, and half of that is incremental to our existing base.

Rodrigo Santos

executive
#10

Above all, we put back more than we introduced, thanks to our unrelenting search for newer, more sustainable solutions. During 2022, as the slide shows, we moved many projects forward, rolled out over 500 new hybrids and varieties in our seed business, and produced hundreds of fresh crop protection product registrations along with several new formulations. This upgrading of better-performing seeds and formulations is essential groundwork for the price improvements we plan to secure in 2023. Our digital tools now cover over 220 million acres. We brought ForGround by Bayer to market successfully — our digital platform that reaches past carbon offsets to assist farmers in shifting toward sustainable practices and in connecting with businesses eager to further their sustainability objectives. It emerged naturally from our Bayer Carbon Program, which now spans 1.5 million acres. We are growing our present leading lineup of biological solutions. Through our open innovation platform, we generate roughly EUR 200 million in yearly sales. That covers the three-year collaboration we formed with Ginkgo Bioworks on nitrogen optimization, carbon sequestration, and next-generation crop protection, our recently announced M2i distribution agreement for pheromone-based biologics, and a strategic partnership with Kimitec on crop protection and biostimulant products.

Rodrigo Santos

executive
#11

Looking ahead to 2023, we have a great many milestones in front of us, and we're excited about where our transformation journey is taking us — empowering farmers everywhere to produce more with less. We're kicking off our U.S. groundbreaker trials for the Preceon Smart Corn System, which brings our breeding approach to short stature corn. Our ThryvOn Cotton — the first-ever biotech trait that protects plants from piercing, sucking sets — is expected to move to a full commercial launch. We're also looking forward to our first-to-business digital solution for in agriculture and adjacent industry through our Microsoft collaboration. To learn more about these advancements and the technology engines that power them, see our investment case on bayer.com and watch for our invitation to our Crop Science Innovation Summit in June in New York. With this innovation in our portfolio and continued strong farm incomes, we see opportunity for accelerating growth in several of our business segments despite the expected glyphosate headwinds. Overall, we're expecting to grow Crop Science sales by around 3%, with glyphosate-based herbicide sales declined by roughly 15% to 20% or approximately EUR 900 million at the midpoint, while the rest of the division sales grow by approximately 8%, mostly from pricing. For glyphosate specifically, we're anticipating that prices will continue to normalize to not fully back to the level seen in 2021, given the higher cost position our generic competitors are facing.

Rodrigo Santos

executive
#12

We anticipate that stronger glyphosate volumes will help counter some of this pricing pressure as our supply comes back near full capacity. This forecast likewise presumes double-digit percentage growth in sales for corn seeds and traits, fungicides, and insecticides, backed by the new innovation, and we are entering the market as well, along with a strong commodity price. Beyond better pricing, we anticipated volume and share gains for corn worldwide and increased volumes from improving supply in our insecticide and fungicides portfolios. Looking at calendarization, the outlook is strongly shaped by the glyphosate burst herb-based herbicide sales trend, given the tough comp in the first half of the year. Total Crop Science sales should be relatively flat in the first half and then speed up in the second part of the year to average 3% for the full year. Turning to the outlook for EBITDA before special items, we continue to expect to lead the industry margin despite some modest dilution versus 2022, with an expected margin in the range of 25% to 26% of sales at constant currency. For the first part, specifically, the margin is estimated to be in the range of 36% to 38%. Additionally, inflation is expected to persist at roughly 4% of sales, largely from higher cost of goods seen in our existing inventories.

Rodrigo Santos

executive
#13

To push back against some of that, we're looking at roughly EUR 300 million of cost savings. The encouraging part is that prices in raw material contracts and costs for transportation are beginning to soften. We anticipate that this inflation in our cost of goods will start to lessen by the close of 2023, which positions us to get back to expanding margins in 2024. With that said, I'll hand things over to Steffen to talk about Bayer Pharma.

Stefan Oelrich

executive
#14

Thank you, Rodrigo, and good afternoon to all of you. To begin with the financial results from last year, Bayer Pharma's sales rose 1% compared with the prior year, driven by greater volumes. Although mature portions of the portfolio presented considerable headwinds, I'm pleased to say that our launch products, Nubeqa and Kerendia, kept delivering very strong performance. As was the case a year earlier, Nubeqa again doubled its sales during 2022, hitting EUR 466 million, powered by continued market growth in non-metastatic prostate cancer. Beyond that, we observed swift uptake of Nubeqa in the metastatic setting. Based on our figures, Nubeqa has already secured its position as the number two product for new patient share in the U.S. across both indications. Kerendia, meanwhile, posted sales of EUR 107 million in 2022, surpassing the EUR 100 million threshold just five quarters after entering the market. Indeed, we are witnessing one of the most powerful launch trajectories in the cardiovascular area, notwithstanding the COVID-19 restrictions we initially encountered during 2021, with ongoing U.S. market uptake fueled by reimbursed access covering most commercially insured and Medicare Part D patients, along with inclusion in treatment guidelines and recommendations. For your reference, we have put together the new prescriptions data for Nubeqa and Kerendia in the appendix of today's slide deck.

Stefan Oelrich

executive
#15

Turning to the rest of our portfolio, Eylea also put in a strong showing, with 9% growth and contributions coming from every region. By contrast, Xarelto sales fell 6% year-over-year, largely because of headwinds in a range of markets — among them the loss of exclusivity in Brazil and pricing pressure in several European countries. A summary of when Xarelto's patents expire in major markets appears in the appendix of today's slide. Most notably, though, China's volume-based procurement rules weighed heavily on Xarelto, cutting our sales in that region by almost half. We've seen comparable effects on Nexavar's full-year sales, and since the fourth quarter we're beginning to see them for Adalat as well — always in China. Finally, 2021 sales included a EUR 190 million milestone payment for Adempas that did not repeat in 2022. EBITDA before special items reached EUR 5.9 billion, 2% higher year-on-year and equal to a 30.5% margin. Foreign exchange movements gave the top line a positive 400 basis point boost, but their effect on the margin was dilutive by 110 basis points, mainly reflecting our high-cost position in territories where foreign currencies appreciated last year. Adjusted for that, the margin matched the prior year and was in line with our guidance.

Stefan Oelrich

executive
#16

Even though we had to contend with considerable cost pressures driven by inflation and a portfolio effect that diluted margins, and these were partly offset by money coming in from divesting smaller non-core businesses. When it comes to what we achieved strategically last year, we made excellent headway and delivered outstanding outcomes in pivotal clinical trials in the mid- and late-stage portion of our portfolio. Thanks to a highly consistent data set from our phase III ARASENS trial, we cleared the path for a broader label for Nubeqa and advanced our goal of establishing this medicine as a foundational therapy across every indication in prostate cancer. With Kerendia, we continue to see a steady stream of positive news and label expansions. Beyond that, phase III results for Eylea 8 mg demonstrated this medicine's potential to transform the treatment paradigm for patients with wet AMD and DME and to become the new standard of care, building on Eylea's gold standard in this category and positioning the franchise for prolonged leadership. Lastly, on the strength of the successful completion of our phase II development program, PACIFIC, we advanced our Factor XIa inhibitor, Asundexian, into phase III. Given these strong achievements, we felt very comfortable upgrading the combined peak sales potential of our launch assets, Nubeqa and Kerendia, to more than EUR 6 billion, and at the same time, we project an equal combined peak sales potential for our phase III assets, Asundexian and elinzanetant combined.

Stefan Oelrich

executive
#17

To frame this more broadly, over the longer term we anticipate that our launch medicines along with current phase III drug candidates will more than compensate for sales erosion caused by exclusivity losses that are coming up—so we would effectively deal with any significant patent cliff worries in the near and midterm. Wrapping up with the innovation progress our Pharmaceuticals division made last year, we broadened our development portfolio further in cell and gene therapies; it now holds six projects spanning various stages of clinical development, among them programs targeting indications with a high degree of unmet medical need, like Pompe disease and congestive heart failure. During 2023, we very much look forward to the readout by mid-year of DA01, our cell therapy study in Parkinson's disease. Beyond that, headline data for elinzanetant from our phase III program, OASIS, will arrive in this year's second half as well. In the interim, we anticipate a steady drumbeat of ongoing approvals for Nubeqa in the metastatic cancer setting across various regions, plus submissions and potentially first approvals for Eylea 8 mg. Turning to 2023 from a financial standpoint, we do expect top line growth of around 1%. Positive momentum from our new products, Nubeqa and Kerendia—for which we foresee combined sales exceeding EUR 1 billion this year—should more than offset market exclusivity losses elsewhere in our portfolio.

Stefan Oelrich

executive
#18

Specifically, we expect Xarelto to see a mid-single-digit decline, with patent expiries in smaller markets such as Mexico, Australia, and Canada also weighing on it. In China, the widening COVID-19 wave early in 2023 significantly restrained hospital sales across the portfolio. Beyond that, Adalat has been affected by the country's volume-based procurement regulations since November last year, and as a result, its sales in this territory in 2023 could fall by up to 50% due to lower prices and volumes, just as happened with Xarelto. By contrast, we expect Eylea to offset price pressure in our territories this year through growing volumes, effectively demonstrating its market leadership. The EBITDA margin before special items should be slightly above 29% at constant currencies in 2023. While we keep driving investments in R&D, we are moving marketing resources away from mature franchises and toward the launch medicines. At the same time, we will manage operating expenses tightly and pursue efficiency measures to mitigate gross margin dilution from pricing headwinds and cost inflation. For modeling purposes, I think it is fair to assume that the first half of this year will be clearly below the second half, both in terms of top and bottom line, since we are likely to see the sales decline from mature assets and the impact of the soft trading conditions in China at the beginning of the year, and then offsetting dynamics from our launch assets.

Stefan Oelrich

executive
#19

You should expect to see quarterly results and our profile getting better in sequence as this year goes on. That's all I have to say about pharma, and I'll hand it over to Heiko for Consumer Health.

Heiko Schipper

executive
#20

Okay. Thanks, Stefan. Hello, everyone. I'm glad to walk you through how our Consumer Health division performed in 2022, and then I'll share an outlook for 2023. Amid a volatile environment, we expanded the business 8.4% to more than EUR 6 billion last year, well above our updated guidance of 6% to 7%. On the bottom line, we made substantial investments in innovation that we expect will deliver strong returns down the road, all while holding a margin of 22.5% in a highly inflationary environment. We also drove considerable cash productivity, lifting our working capital to sales ratio by 220 basis points. Here's what stands behind those results. First, growth was again very broad-based. Every region and every category chipped in. Over the past few years, demand has shifted in unprecedented ways in categories such as Nutritionals and, more recently, Cough and Cold. Despite those shifts, we delivered consistent growth by drawing on the strength of our category footprint. We concentrate on categories where sound science, innovation, and strong brands make the difference. Our success over the past few years shows that this focus is the right one. Growth in 2022 was driven by a high incidence level of cold and flu versus a soft previous year, with strong demand for our products throughout the year.

Heiko Schipper

executive
#21

We also recorded meaningful expansion in our allergy segment thanks to the Astepro launch. In Dermatology, where we kept rolling out our Bepanthen Derma innovation — a science-based line for dry skin — growth was just as strong in 2022. Following 2 years of considerable expansion in our Nutritionals category, 2022 brought more modest growth, though at an absolute level well above where we stood before COVID-19. That result demonstrates our ability to guide the business through uncertain conditions. We seized growth opportunities, lifting the e-commerce share of sales to roughly 11% at present. We entered new growth markets such as India. Our wide-ranging productivity programs were carried out successfully, applying pricing actions to offset inflation and to fund innovation. Even with pressure from strained supply chains, we managed to serve customers and hit or beat our targets. That holds too for our EBITDA before special items goal. In addition, global supply chains stayed constrained and high inflation affected markets everywhere. We raised EBITDA before special items by 15% to EUR 1.4 billion, and our EBITDA margin before special items came in at the prior-year level of 22.5%, matching our guidance.

Heiko Schipper

executive
#22

We offset considerable cost pressure from inflation by leaning on our operational productivity initiatives and by managing pricing actively. Meanwhile, we kept making sizable investments in innovation as well, especially for the Astepro launch in Q3, 2022. That is something our colleagues in Crop Science and Pharma are aware of.

Operator

operator
#23

We ask that you remain on the line, as the conference will be back with you in just a moment.

Heiko Schipper

executive
#24

When it comes to competing products, this solution is genuinely differentiated and will generate meaningful incremental growth for our leading allergy business. On the digital side, we teamed up with Huma Therapeutics — a top digital health company — to bring out an innovative personal health tool that assesses a person's risk of developing cardiovascular disease over the coming 10 years. Using easy-to-answer questions, a sophisticated algorithm, and research with scientific backing, the Bayer Aspirin Heart Health Risk Assessment provides people with actionable insights they can bring into conversations with their doctor about heart health. The initial rollout of the tool will happen in the U.S., where more than 100 million people may face cardiovascular disease risk. In our view, applying digital technology to healthcare can reshape how people look after themselves in the years ahead by giving them insights that lead to smarter health decisions. Lastly, we also made innovation progress in Nutritionals, a category that stayed profitable even following remarkable 12% growth in 2021 and 23% growth in 2020. We introduced a new immunity formulation under our Supradyn, Redoxon, and Berocca brands. Seven clinical trials back the formulation we launched, supporting every layer of the immune system to help people get healthy and stay healthy.

Heiko Schipper

executive
#25

As we turn our attention to 2023, innovation is set to serve once more as a major engine of growth. Our entire focus is on ensuring Astepro becomes the go-to nasal spray during the coming U.S. allergy season. Later in the year, we also intend to introduce an innovative personalized health offering. In addition, we will keep our disciplined approach to steering the business firmly in place. We anticipate sustained elevation and ongoing inflation through the first half of the year, before things normalize in the second half. Even under these conditions, we are ready to push our margin progression further while we keep investing in innovation and brand building that powers future growth. Those priorities add up to another competitive business outlook for 2023. Although we foresee continued growth across our industry, our plan is to grow at the top of the industry, with sales growth of around 5%. Consistent with our midterm ambition, we are targeting a rise in EBITDA margin before special items to around 23% at constant currencies. With that, I'm glad to pass things over to you, Wolfgang.

Wolfgang Nickl

executive
#26

Okay, thank you, Heiko. Now let's turn to the group financials for 2022, along with a combined outlook for fiscal 2023, drawing on what my colleagues have just presented. Last year we met or actually surpassed every relevant guidance parameter for the group. Group net sales, adjusted for currency and portfolio effects, rose 9% to EUR 50.7 billion, which was in line with our upgraded guidance range. That CPA growth came mostly from pricing. The top line in 2022 also got a lift from currency tailwinds of roughly EUR 3 billion. The main drivers there were the strength of the US dollar, the Brazilian real, and the Chinese RMB against the euro. Our top line growth fed through into a 21% rise in EBITDA before special items, reaching EUR 13.5 billion. That works out to a margin before special items of 26.6%, above the top end of our guidance range. As we had expected, foreign currency effects of about EUR 430 million were less pronounced on EBITDA than on sales, which produced a margin dilution of roughly 80 basis points. Core earnings per share came in at EUR 7.94, ahead of our upgraded guidance and 22% above the prior year. Divisional contributions were led by Crop Science and more than offset a negative year-over-year impact in the core financial result, which stemmed from higher interest expenses and non-cash relevant fair value changes, consistent with our full year guidance.

Wolfgang Nickl

executive
#27

Core tax expenses came in at EUR 2.1 billion, which was comparable to last year in absolute terms. That reflects a lower core tax rate of 21.7% applied to higher earnings. Our free cash flow more than doubled, reaching EUR 3.1 billion, primarily driven by lower settlement payments versus the prior year. Settlement payments totaled EUR 1.2 billion, and that figure did not include the roughly EUR 700 million payout for the Oregon settlement. Both the Oregon settlement and the municipal water class settlement were paid at the start of this year and are factored into our financial guidance for 2023. Net financial debt fell to EUR 31.8 billion at the end of 2022. A higher free cash flow contribution, along with EUR 3.4 billion in divestment proceeds from the sale of the Environmental Science Professional business and other non-core assets in pharma, was partially offset by approximately EUR 2 billion in dividends paid and around EUR 2 billion of negative impact from foreign exchange effects. Let me now turn to our guidance for 2023 at the group level. We expect group net sales of EUR 51 billion to EUR 52 billion at constant currencies, which represents 2% to 3% currency and portfolio adjusted growth. As for currency impact, we estimate a headwind of around EUR 1 billion in 2023, based on the month end December spot rates compared to average actual prior year rates.

Wolfgang Nickl

executive
#28

The primary driver here is the U.S. dollar. As for the other KPIs, at this stage we aren't shielding the material impact stemming from foreign exchange rates. When you're modeling, keep in mind that our group net sales guidance incorporates a negative portfolio effect of roughly EUR 500 million tied to the businesses divested in 2022. Regarding phasing, we anticipate business performance will lean toward the second half of this year relative to 2022. Turning to our bottom line, we forecast EBITDA before special items of twelve and a half billion EUR to 13 billion EUR. Price declines in glyphosate and pharma, cost inflation, and growth investments should be partly offset, we expect, by active pricing management in the non-glyphosate Crop Science business and Consumer Health, along with cost savings of about EUR 500 million to EUR 600 million across the company. For Core EPS, our expectation is between EUR 7.20 and EUR 7.40 for 2023. I'll return to the Core EPS bridge once I've finished the guidance. We stay focused on managing cash effectively. We're planning on free cash flow of around EUR 3 billion for the full year, even with higher net settlement payouts of around EUR 2 billion to EUR 3 billion.

Wolfgang Nickl

executive
#29

That gives us underlying free cash flow before settlement of roughly EUR 5 billion to EUR 6 billion for 2023. We expect net financial debt to come in somewhat above last year's level, at EUR 32 billion to EUR 33 billion, and that figure includes larger dividend payments during 2023. Then, on the remaining guidance parameters, I'd point out that our reconciliation result should land between -EUR 700 million and -EUR 800 million. That number incorporates the catch-up effect from our long-term incentive provision, which is based on a share price assumption of EUR 60. An overview of all the other guidance elements is included in the backup to this presentation. Let me return to Core EPS briefly. I'd like to walk through an illustrative bridge covering 2021 to 2022 and then 2022 to 2023. During 2022, higher glyphosate pricing contributed roughly EUR 2.07 per share. The pre-tax impact stood at EUR 21.00. Material cost inflation hitting all of our divisions offset that by approximately the same amount. As I said earlier, the core financial result and core taxes together had a negative effect, while foreign exchange tailwinds worked in our favor. Absent those effects, underlying business performance added EUR 1.93 to core EPS year-on-year.

Wolfgang Nickl

executive
#30

Looking ahead to 2023, our bold blueprint once more features a substantial boost from the base business, landing somewhere between EUR 2.20 and EUR 2.40. As my colleagues laid out, that figure reflects anticipated stronger pricing out of our Crop Science portfolio, glyphosate excluded. On top of that, we anticipate volume increases in corn, sizable input from our launch work in Pharma, and growth in Consumer Health that outpaces the market—all of which should add to the cost savings already noted. Rodrigo brought up the expected normalization of glyphosate pricing, which should be partly offset by larger glyphosate volumes. In total, we see that producing an effect of roughly minus EUR 1.40 on core EPS. Cost inflation should keep weighing meaningfully, to the tune of about EUR 1.60 per share on a pre-tax basis, driven in particular by more highly valued inventories that will flow through our P&L during this year. Consequently, given the persistently elevated macro volatility we anticipate, our guidance points to a core earnings per share range of EUR 7.20 to EUR 7.40 for fiscal year 2023, as I said earlier. That said, I'll turn things back to you, Oliver, so we can get the Q&A started, please.

Oliver Maier

executive
#31

Thanks. Thanks a lot, Wolfgang. Appreciate everyone's insights. Before we get started, a quick reminder to please limit yourselves to roughly 2 questions per person, so we can get to as many participants' questions as possible and try to avoid using headsets. That makes things easier on our end. Heidi, if you wouldn't mind opening the line for questions, that would be perfect. Thank you.

Operator

operator
#32

Certainly. Just a reminder that to ask a question, you'll need to press star one and one on your telephone and wait for your name to be announced. If you'd like to withdraw your question, please press star one and one again. We'll take our first question now. Our first question comes from the line of Michael Leuchten from UBS. Please go ahead. Your line is open. Michael Leuchten, your line is open. Please ask your question.

Michael Leuchten

analyst
#33

Sorry about that — this is Michael Leuchten at UBS. I have one question for Wolfgang and another for Stefan, if I may. Wolfgang, I just want a clarification regarding how the P&L is phased across the year. Could you spell out where you stand on hedging energy costs for 2023? As a percentage of the total, how much is hedged? Does that change over the course of the year, first half versus second half? On your comment about inventory and first in, first out — does that mean that up until Q3, once we get past your typical 50 days of inventory, the P&L is going to be distorted quite a bit, and then in Q4 things return to normal? Then a question for Stefan. What happened during the fourth quarter? From a revenue standpoint you were on course to hit guidance, and then we saw a decline. Why did that suddenly occur in Q4? As we look ahead to 2023, is the whole story about new products building momentum, or was there something in the mature portfolio in Q4 that could also normalize during the first half? Thank you.

Wolfgang Nickl

executive
#34

Okay, Michael, I’ll try to break this down for you. Those EUR 500 million to EUR 600 million in cost savings I brought up were tied to the initiatives we made public two years back. They’re continuing to come through from that EUR 1.5 billion+ program, and the benefits are spread largely across Crop Science, Pharma — as Rodrigo mentioned — and enabling functions as well. Some of that, frankly, also gets plowed back into the business. Energy accounts for a fairly modest share of our costs — call it roughly 3%. Clearly, hedging in 2022 and 2021 was simpler than hedging 2023 versus 2022, since prices were running high. Assume a manageable year-over-year effect, and energy prices are beginning to ease. Even so, we still expect roughly EUR 1.6 billion of inflation this year, energy included, and that covers active ingredients, freight — which is declining but remains above the 21 level — and frankly labor too. A good deal of this is already reflected in inventory. You’ve likely noticed that our inventory rose by around EUR 2 billion last year.

Wolfgang Nickl

executive
#35

We weren’t caught off guard. This was deliberate: at one point we worried that energy availability might become a problem either for us or for our suppliers, so we let inventory run a bit higher than normal. Clearly, inflation’s effects are also baked into that inventory. On the quarterly phasing, you’re exactly right. That inventory typically gets used up—sometimes FIFO, though at minimum under an average-cost method. As the year progresses, COGS then carries the higher inventory cost. Hopefully, if we’re able to purchase at lower prices again during the year, that will benefit the P&L and in the second half of the year as well. Your interpretation is correct. Stefan, over to you.

Stefan Oelrich

executive
#36

Hi, Michael. Yeah, there were some unusual effects in the fourth quarter that we observed. First, naturally, is the launch of Adalat VBP. That kicked off right at the start of Q4. During December and, frankly, January as well, we saw very weak demand in China, since a lot of people stayed home due to their COVID infections. Within our own workforce, a tremendous number of our employees were hit by the illness across those two months, and that probably mirrors what took place in the country and the absence of demand we witnessed, particularly in December and January. On top of that, there was continued weakness in our U.S. women's healthcare business during the fourth quarter relative to our plans. That's the combination that answers your question, at least I hope so.

Michael Leuchten

analyst
#37

I appreciate that.

Stefan Oelrich

executive
#38

Thanks, Michael.

Operator

operator
#39

Thanks. We’ll move on to the next question. Our next question is from James Quigley at Morgan Stanley. Please go ahead. Your line is open.

James Quigley

analyst
#40

Hi there. Thanks for taking my questions. James Quigley from Morgan Stanley. I have two, please. The first is on the pharma margin. Near term, as you said, sports and the new launches, R&D and inflation are going to affect it. How should we think about charting a course back to margins in the low 30s? Is that achievable purely through mix as the newer assets begin to grow and the U.S. business becomes less of a drag on profitability, or would it take additional cost savings or restructuring to get back to those levels? Second, on the PCB litigation, could you walk us through the process for the indemnification claims? What are the next steps? What potential timing is associated with those? How difficult or easy is it to identify the third parties, given that this goes back to the late 1970s? Also, if you could update us on any potential timing of the appeals for the PCB litigation as well. Thank you.

Stefan Oelrich

executive
#41

Thanks, James. You basically answered it yourself in the question. The improvement in margin is going to be driven to a great extent by mix, and over the coming years that mix will come from a much stronger situation in the U.S. We can already see right now that the U.S. is the fastest-growing region for us anywhere in the world. At the same time, we're very aware that costs need to be managed tightly, and that is exactly what we plan to do. And keep in mind that as our mix improves for the U.S., we have somewhat more latitude on pricing than we do with the Europe business that is over-indexed for us today.

Werner Baumann

executive
#42

Okay, James, I’ll address your PCB question. To start, two settlements have already been paid out as of early 2023. The first is the Oregon State settlement you know about. The second involves the roughly 2,500 municipalities we settled with. We’re still pursuing a number of state claims, including Maryland, Pennsylvania, New Jersey, and Illinois. Those, along with a few others, will likely move forward in the future. Next, there’s the Sky Valley buildings complex, where we’ve lost several cases and are appealing them. We’ve also had one mistrial. As for the so-called undertakers—our customers from the sixties and seventies—virtually all of our major customers are clearly identified, and their successor companies still exist. We hold very, very comprehensive indemnity claims against them. We filed in court last year to activate those claims. At the same time, we’re talking with them and negotiating. On timing for these specific matters, if you look at the indemnity lawsuits, the first trial date scheduled is no earlier than quarter four 2024.

James Quigley

analyst
#43

Alright, thanks.

Operator

operator
#44

Thanks. We’ll move to the next question now. Please hold. Our next question is from Richard Vosser at J.P. Morgan. Go ahead. Your line is open.

Richard Vosser

analyst
#45

Hi. I appreciate you taking my question. I have a question regarding the glyphosate pricing assumptions. We can observe, sort of, Chinese glyphosate pricing dropping to, sort of, average 2024 levels right now in February. 21. Sorry. Average 21 levels in February 2023. How should we think about that EUR 2 billion pricing benefit? Obviously, as you mentioned, some of it is retained. Could you provide us with more detail on what benefit you believe is retained in 2023 and how you expect that to develop in 2024? Would you expect further price reductions there? Maybe some indication of the revenue impact from volumes. I recall back in the day when Luling was out of commission, it was something in the region of EUR 200 million to EUR 300 million of revenue loss. Is that the sort of volume loss as well? Some assistance there would be great. Second question, just on pharma, just on the hemophilia franchise. We have seen a new factor eight from Sanofi getting approved. Of course, there is continued competition from Roche, his product as well. Just how do you see that impacting the Coagenate franchise going forward? Thanks very much.

Werner Baumann

executive
#46

Thanks, Richard. I'll start us off here, and then hand things over to Stefan. Regarding glyphosate, our guidance calls for a EUR 900 million decline. That reflects both price and volume. We indicated we'd land in the 15% to 20% range below last year. Price works against us there, while volume works in our favor. As we noted, volume in the last two years — for the first time, at the close of 2021, the hurricane was still hitting us. That carried into early 2022 as well. This year marks the first time we'll have glyphosate's full volume. That gives us a bit of a lift. All told, the average comes to a EUR 900 million step down from last year, which is what we've built in for this year.

Stefan Oelrich

executive
#47

Hi, Richard. First off, whenever innovation shows up in the category, it's always encouraging to see, even when it comes from competitors, since patients benefit from that. Regarding our hemophilia business, I have to say I'm genuinely pleased with how resilient it has proven to be, particularly over the last year. Looking at the total year, we've been pretty much flattish across the year, given all of these new entrants. Our bigger challenge right now in our hemophilia business is that we're moving patients from Coagenate into the Kovaltry product and into Jivi, the longer acting factor eight. But we're seeing very strong loyalty to our brand. Yes, this is getting more difficult, and I would anticipate that we're going to be not growing this business, but I'm quite positive about the resilience, but there is a negative trend here.

Richard Vosser

analyst
#48

I appreciate that.

Stefan Oelrich

executive
#49

Thanks, Richard.

Operator

operator
#50

Thanks. We'll move on to the next question. Our next question is from Keyur Parekh at Goldman Sachs. Please go ahead. Your line is open.

Keyur Parekh

analyst
#51

Hello there, and good afternoon. Thanks for taking my questions — I have two, if I may. The first concerns Crop. When we look at 2023, you're indicating EUR 900 million of headwinds from glyphosate, and excluding that, you expect the remainder of your Crop portfolio to grow 8%. I'm curious whether you can give us a feel for the business overall. What are your expectations for the pricing and volume dynamics? In 2022, price was 16% and volume was 0%. Given that, what do you expect price versus volume to be, roughly, for your Crop business in 2023? On a separate note, how should we think about your outlook for the soybeans seeds and traits business, considering the ongoing penetration for Enlist and the situation surrounding dicamba registrations? Thank you.

Werner Baumann

executive
#52

Thank you. I'll take your question as a chance to offer a reflection here. After just 1 year in this role, I really feel we closed out 2022 as a very strong year, and I feel that what we planted for 2023 is working the way we designed it. Let me share a bit about what we planted for 2023, right? For corn seeds and traits, fungicide, and insecticides, we're planning double-digit growth. That will come from a combination of pricing and volume. We're also picking up some volume and some market share as well. That's one of the elements in our plan. As we knew — because we've been managing this glyphosate business for 25 years now — we knew this would be coming for us. I think we planted in the core business to really drive the growth we're planning for next year. That's why, for that business, we are projecting 8% average growth for 2023. That's what we are driving here. When you think about pricing of those elements, we launched pricing in the northern hemisphere, and that was very successful so far. We are in the middle of that campaign. We launched it in U.S.

Werner Baumann

executive
#53

And in Europe, we're seeing what we refer to as a low double-digit price increase. We still have to launch in the southern hemisphere at the end of the year — or the middle of this year, sorry. We're going to see that one coming. We feel good about the innovation we have here. What I want to stress is that, when you think about 2023, the launches we have in corn, soybean, cotton, our CP, our biologics, the new technologies we're bringing, such as the Preceon Smart Corn System with short stature corn — this will drive a bit of the growth in 2023 and, even more importantly, the years ahead of us. Soybean — let me address your questions on soybean, right? We were flat last year, and that came from a combination of higher growth in Latin America along with lower sales in North America, mainly because of excess seed and also because of the trade share. On your question about the trade share: Enlist has been gaining trade share over the last years, basically because Corteva was migrating their germ plasma with their trade platform out of extent. What we see today, and what we see for 2023 and for 2024, prior to the launch of ATT four, is that we're now seeing more of an equilibrium market.

Werner Baumann

executive
#54

They do adjust their holdings, but at this point the rivalry is more mark-to-market, and it will combine germ with the technology trade, and our confidence is high. We remain number one in the U.S. and, by a wide margin, in South America too. Soybean sales total EUR 2.5 billion, which puts us ahead of the second company in the market. That market is still ours to lead. Going forward, what we see is more of a balance, a competitive market where we'll fight for every acre in the U.S. and in South America as well. We feel good about this year, but even more so we are planning and working toward launching the new technologies still to come. Thank you for your questions.

Operator

operator
#55

Thanks. We'll move on to the next question, which comes from Peter Verdult at Citigroup. Please go ahead — your line is open.

Peter Verdult

analyst
#56

Thanks. Peter here from Citi. Rodrigo, might you give us a rough update on digital ag revenues right now, plus licensing revenues throughout your seeds business? The rationale behind my question is that I'm attempting to gain a rough idea so I can gauge, you know, the relative materiality against the present business, since, you know, all of us can grasp that the digital ag part of the business is going to increase and grow nicely, yet in the same way, there will be downward pressure from erosion of licensing revenue coming from your partners. I simply wanted to dig into that subject a bit further. Stefan, returning to Eylea, you made a few comments regarding 2023. Is that, net net, a flat year or modest growth? Even more significantly, what is your thinking on Eylea 8 mg over the long term? I believe you've stayed cautious from the moment we saw the data, contending that patent extensions will be hard to secure in Europe and key international markets. Has, you know, now that things have calmed down and you're beginning to file the 8 mg formulation, your perspective on the long-term outlook for Eylea shifted at all? What I mean is, those of us in the market have modeled it eroding, but I was hoping to hear the most current view on the long-term outlook for Eylea.

Peter Verdult

analyst
#57

Appreciate it.

Rodrigo Santos

executive
#58

Thanks for raising that — it's a really important question, and let me try to clear it up. As things stand, licensing is a EUR 2.6 billion business for us. Of that total, under 10% goes to the large multinationals such as Corteva and Syngenta. The remaining 90% of licensing comes from regional or small seed companies that we work with around the world. That's the reason we expect our licensing business to keep growing. Beyond that, looking at the midterm and the launch opportunities I mentioned earlier — corn, soybean, ThryvOn and cotton — we see even more opportunity ahead. Right now, 90% is regional and small companies. Stefan?

Stefan Oelrich

executive
#59

Peter, thanks for that question. On Eylea, what we're observing is that volumes continue to grow nicely, though we are running into some pricing pressure, particularly in Europe and possibly in other regions as well. On the whole, this won't represent the kind of success we enjoyed in earlier years. It's still slightly positive, but for 2023 it won't match prior years. To repeat, volume growth remains solid, but prices are difficult. Regarding 8 mg, I believe — and I've mentioned this previously — that it will provide Eylea with renewed additional life beyond the loss of exclusivity for the 2 mg in the years ahead. Where many people probably anticipated a declining Eylea in the coming years, we should now see an outlook that is much more stable and perhaps even growing for Eylea over the next two to three years. Compared with some of the forecasts that came from outside, I think that is genuinely a positive.

Werner Baumann

executive
#60

Yeah, Peter, just to be clear on that. I think we were going back and forth on whether part of what you asked had to do with digital, right.

Peter Verdult

analyst
#61

Correct.

Werner Baumann

executive
#62

Regarding digitization, what you currently have and how that business is performing.

Peter Verdult

analyst
#63

Yes.

Werner Baumann

executive
#64

So,

Peter Verdult

analyst
#65

Yeah, that was correct. Yeah, thanks.

Stefan Oelrich

executive
#66

Rodrigo will also address that point.

Rodrigo Santos

executive
#67

Oh, that's excellent, Peter. And it's a really key piece too. Let me spend a moment on digital. This year we hit 220 million acres with FieldView. That's 23 countries now, and the first country in Asia — Australia — where we also have a very successful business. There are two other elements I want to share that I think are very important. The other one is that we launched the digital platform in the U.S., which is ForGround. We're connecting companies that are working to reduce their sustainability or their carbon emissions with farmers, right? The Purdue business is a good example of that. We are connecting — I think Bayer has a very good position connecting those companies with farmers because of our footprint, our presence in the field. ForGround is the digital platform that I feel very excited about next year. Another two examples on digital that we're gonna see in the midterm, with a lot of new things coming. One is our collaboration with Microsoft, and 2023 probably will be the first year that we're gonna see some business coming out of that. Finally, if you go to South America, we had a very successful launch with a bank there on Orbia, our platform, expanding also credit terms on the digital platform.

Rodrigo Santos

executive
#68

Peter, I'd say we're going full speed on developing those digital platforms. You also heard from Heiko that Consumer Health is reaching 11% of sales. We're expanding those platforms around the world. I'm sure that when we look at next year and the midterm, we'll see a great deal coming from that side too. Thanks for your question on that.

Peter Verdult

analyst
#69

Thanks. Appreciate it.

Stefan Oelrich

executive
#70

Thanks.

Operator

operator
#71

Thanks. We’ll move on to our next question. Our next question is from Laurent Favre at Exane BNP Paribas. Go ahead. Your line is open.

Laurent Favre

analyst
#72

Good afternoon, everyone. Actually, I have two questions for Stefan. First, about R&D spending — as a share of sales, I believe it hit a record high last year. Could you share your view on how that will trend in 2023? Second, I'd like some clarity on whether you expect the division's 2024 margins to be higher than in 2023. Thank you.

Stefan Oelrich

executive
#73

Thanks, Laurent. I’d be glad to pass that question along to the Head of R&D. For this year, I can say we expect a modest rise in what we spend on R&D. That is the sole line where we genuinely leave room for higher spending, since we’ve stated that directionally over roughly the next decade we will move more toward 20%, while still keeping our overall profile in good shape. Regarding where the margin goes in 2024, 2024 will clearly be a continuation of the Xarelto erosion. Our margin faces substantial pressure in the... For as long as Xarelto keeps eroding when a product of that scale is lost. That said, our launches are offsetting this quite well, and those launches demand considerable investment.

Laurent Favre

analyst
#74

When you were at the Capital Market Day in 2021, you mentioned margin pressure of roughly 200 basis points for 2024 versus 2023. Should we be expecting that same kind of pressure then?

Stefan Oelrich

executive
#75

Could you say that again? I wasn’t able to hear you.

Laurent Favre

analyst
#76

Back at the 2021 Capital Market Day, you guided pharma margins lower by roughly 200 basis points across 2023 and 2024. So I'm wondering — is that kind of decline what we should be expecting for 2024?

Stefan Oelrich

executive
#77

At this point, honestly, it's quite hard to square things with the 2021 guidance we provided, since VBP ended up hitting us in the middle to a far bigger extent than anyone expected back then. And on top of that, we've got the Xarelto patent extension in Europe running until 2026. Reconciling those figures right now is tough.

Laurent Favre

analyst
#78

Alright, thanks.

Stefan Oelrich

executive
#79

Thanks, Laurent.

Operator

operator
#80

Thanks. We'll move on to the next question. Our next question is from Sachin Jain at Bank of America. You can go ahead. Your line is open.

Sachin Jain

analyst
#81

Sachin Jain here from Bank of America. I have a few quick clarifications, if I may. First, regarding glyphosate and that EUR 900 million decline you mentioned — do you see that as an aggressive goal or a cautious one? Could you also share whether your assumption includes any price stabilization, given that pricing is still falling? Stefan, on Eylea, could you quantify the pricing pressure you're observing and where it's coming from? I'm just trying to gauge whether you expect that to speed up in 2024 and 2025. As for the volume growth you anticipate, what Vismo effect are you factoring in? My final question concerns Kerendia — I accept the positive remarks you're making and the strong CV launch despite COVID. EUR 200 million in sales for 2023 remains modest compared with your absolute peak of EUR 3 billion. Would you walk us through what you see as the next steps to get there — what are the key obstacles? Is it payers? Is it feedback from physicians? Is it positioning against SGLT2s? Thank you.

Werner Baumann

executive
#82

Regarding glyphosate, just quickly—we've touched on this a bit before. We provide roughly 40% of the market. The remaining 60% of the market still comes from China. It's really difficult for me to assess that portion of the market. We watch it very closely. One lesson we've picked up across the last 25 years of managing glyphosate is that we run a very lean operation, very tight, with very low rebates tied to the season, and we operate in a manner that lets us stay very agile here. We believe that what we're guiding for the year—taking into account as well the costs affecting not just us but the generic companies too—is the correct guidance. We'll keep watching that and responding to the market. I believe that our plan, as you mentioned, combining price decline with volume upside, is the right guidance for the year, and we'll keep monitoring that market.

Stefan Oelrich

executive
#83

Thanks for that question, Sachin. Regarding Eylea, my expectation is that pricing will be more pronounced in 2023 than in the years after, since in those later years we'll have the 8 mg standing against it, so to speak. The pricing pressures we're seeing are across multiple European markets and in Canada, particularly this year. And it can sometimes be a bit difficult to predict which month it's going to hit you. We anticipate that happening this year. And on Corvidia, thank you for recognizing the good launch. What we're seeing is that, apart from anything else, educating physicians wasn't easy for us in the launch year, frankly, because our reach and frequency were very much impaired. We're catching up on that front. At the same time, you've seen that we're doing very well on guidelines. What stands out most on guidelines, I think, is that they're starting to recognize that SGLT2s and mineralocorticoid receptor antagonists — and in fact they now name only Corvidia, because it's the only one that works, since it has a clean side effect profile. They're being strongly differentiated in the guidelines. I think we're going to see this materialize in clinical practice, because Corvidia is the ideal solution to add to an ACE or ARB, given its mechanism of action, which is the baseline therapy for all renal patients.

Stefan Oelrich

executive
#84

Our expectation is that this will provide considerable momentum as we move into our cardiovascular indications as well. As you're aware, a trial is currently running on our side in heart failure, and we are looking at ways to broaden the data we generate in that area, since we observe that the way a mineralocorticoid receptor antagonist works is increasingly coming into focus. That leaves us with high hopes for the drug. Keep in mind that another major indication is on the horizon.

Sachin Jain

analyst
#85

I appreciate that.

Stefan Oelrich

executive
#86

Thanks, Sachin.

Operator

operator
#87

Thanks. We'll move on to our next question. Our next one is from Christian Faitz of Kepler Cheuvreux. Go right ahead. Your line is open.

Christian Faitz

analyst
#88

Yes, thanks. I have two questions, please — one for Rodrigo and one for Wolfgang. Rodrigo, on the Crop Science side, how do you expect seed production costs to develop this year, in both the northern and the southern hemisphere? Then for Wolfgang, you have around EUR 12 billion of bonds and notes that need to be refinanced, or ideally even retired, over the next three years. From today's perspective, can you give us your assessment of incremental interest rates? Thank you.

Stefan Oelrich

executive
#89

Hello?

Wolfgang Nickl

executive
#90

Apologies, apologies. Let me begin with seed production and share a bit on that. As you’re aware, a great deal of our production is very local. Because of that, we run into challenges such as drought in Argentina or in certain other regions around the world. On the whole, when I put together the market average, doing this local production exposes me to dilution risk. I believe we’re in good shape to offer farmers, for next year, the campaign we have planned. The growth we’ve planned for the corn business — one example being double-digit growth, combining price and volume — is backed by the seed production we have today.

Christian Faitz

analyst
#91

All right, thanks.

Stefan Oelrich

executive
#92

Appreciate the question about debt and refinancing too. I'd say you're roughly in the right area. Over the coming 2 to 3 years, sizable bonds and hybrids mature, so we'll also have some refinancing to handle, which of course hinges on free cash flows and similar factors. Don't hold me to this, but suppose roughly EUR 7 billion of refinancing from now through 2025 — the arithmetic is quite straightforward. Each 1% equals EUR 70 million. Were we refinancing today, using the same 10 years and the same mix, you'd likely be looking at around 3% or thereabouts. Rates have been softening somewhat. That would then be countered by lower net financial debt. On balance, it would come in below that. That's probably a useful benchmark for you.

Christian Faitz

analyst
#93

Thanks — that's really useful, Wolfgang and Rodrigo.

Stefan Oelrich

executive
#94

Thanks, Christian. Heidi, I believe we're scheduled back to back here. There's another meeting right after this. We can fit in one final question, Heidi.

Operator

operator
#95

Certainly. Appreciate it. Please hold. Our final question is from Vincent Andrews at Morgan Stanley. Your line is open — go ahead.

Vincent Andrews

analyst
#96

Thanks for fitting me in — I appreciate it. Rodrigo, I was just wondering whether you could say a little about the seed order book for the North American season. As we sort of look toward March here, where do you stand coming in? Is it earlier than expected, on time, or something along those lines? And are you seeing any kind of benefit from the fact that fertilizer costs for farmers are much lower year-over-year, so that farmer economics this year are actually even better than last year in terms of what they can put toward the seed portfolio?

Rodrigo Santos

executive
#97

Well, Vincent, that's an excellent question. I was reviewing that USDA material last week. Farm economics for the U.S. this year are lower than last year, but still above the 20-year average, right? The farmers' farm economics are still somewhat positive. That's why we're considering a recovery in corn acres. Last year, we had a -5 million. I'm sure you remember that one. There will be a recovery of corn area that we are seeing. How much will that be? This is a little bit to be defined, but we are considering that one. When we look at our orders book, we see all the adoption of the high technology. That's a good indication as well that we are having a good season, Vincent. Again, should be another good year for the Northern Hemisphere as we see.

Vincent Andrews

analyst
#98

All right, thank you so much.

Stefan Oelrich

executive
#99

Thanks, Vincent. All right, that appears to be the final question we had room for. Thanks to all of you for joining us today. We really appreciate it. We'll be speaking again before long. Many thanks. Take care, everyone.

Operator

operator
#100

That wraps up today’s conference call. Thanks for taking part. You’re welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.